Incyte Corp (BSP:I1NC34)
R$ 221.1 0 (0%) Market Cap: 85.19 Bil Enterprise Value: 74.99 Bil PE Ratio: 552.00 PB Ratio: 4.70 GF Score: 77/100

Incyte Corp at Goldman Sachs Global Healthcare Conference Transcript

Jun 14, 2022 / 03:00PM GMT
Release Date Price: R$188.87
Unidentified Analyst

Good morning, everyone. Thanks for joining us, and welcome to day 2 of the Goldman Sachs Healthcare Conference. We're really pleased to have the Incyte team with us. We have Herve Hoppenot, Chairman, President and CEO; and Christiana Stamoulis, CFO of the company. So with that, Herve, happy to turn it over to you for any opening comments or we can just jump right over into questions.

Herve Hoppenot
Incyte Corporation - Chairman, President & CEO

No, good morning. I think we can jump to the questions because there are a number of moving parts at Incyte. So let's go.

Questions & Answers

Unidentified Analyst

So product diversification has been a focus for Incyte. And at this point, you now have Jakafi, Pemazyre, Monjuvi, OPZELURA and the pipeline here. So what is the outlook that you have for the business over the medium and longer term?

Herve Hoppenot
Incyte Corporation - Chairman, President & CEO

So the business strategy is growth, and we are

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot